Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Week Liechtenstein.
Press releases published on October 6, 2025
Newsmatics Team to Speak at Mid-Atlantic MarCom Summit on AI’s Impact on News Consumption, Distribution
Newsmatics’ Oct. 9 panel at the MarCom Summit offers actionable insights into AI-driven media trends and discoverability WASHINGTON , DC, UNITED STATES, October 6, 2025 /EINPresswire.com/ -- Newsmatics is proud to announce its hosting a panel discussion …
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at …
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil® (remestemcel-L-rknd) sales for the …
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
Carlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced a series of key leadership and governance changes aimed at strengthening its executive team, enhancing financial transparency, and …
Court Dismisses Key Fraud Allegations in LuxUrban Securities Case, Leaving Narrow Disclosure Dispute According to New Stanford Legal Report
Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- U.S. District Judge Paul Engelmayer ruled that claims related to LuxUrban’s Q1 2024 financial statements failed to meet the standard for pleading fraud. As a result, the core financial fraud allegations …
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both patients …
FOBI AI ANNOUNCES LAUNCH OF “FOBI AI 3.0” — STRATEGY. ARCHITECTURE. EXECUTION.
Vancouver, BC, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Fobi AI Inc. (OTCQB: FOBIF, TSXV: FOBI) (“Fobi” or the “Company”) announces the formal launch of Fobi AI 3.0, a new strategic and operational framework that aligns the Company’s consulting, licensing, and …
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Châtillon, France, October 6, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a …
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
Châtillon, France, 6 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « Société » ou « DBV ») (Euronext : DBV …
NowVertical Retires Debentures in Full, Strengthening Balance Sheet
TORONTO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (TSXV: NOW) (“NOW” or the “Company”), a leading data and AI solutions provider, is pleased to announce that the convertible debentures of the Company which were issued on October 5, 2022 ( …
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more LEQEMBI IQLIK, approved …
Biomea Fusion Announces Proposed Public Offering of Securities
SAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and …
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
$5 million tranche received under up to $20 million financing agreement IND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) …
Gaming Arts LLC Announces Partnership with Inspired Entertainment to Bring Online Titles to North and South American Land-Based Markets
LAS VEGAS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Gaming Arts LLC is proud to announce a new partnership with Inspired Entertainment, Inc., a leading B2B provider of gaming content, technology, hardware, and services. The collaboration will adapt Inspired’s top …
SAIC to Acquire SilverEdge Government Solutions
RESTON, Va., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Science Applications International Corp. (NASDAQ: SAIC), a leading mission integrator supporting defense, space, intelligence and civilian agencies, announced today it has entered into a definitive agreement …
Sprout Social to Announce Third Quarter 2025 Financial Results on November 5, 2025
CHICAGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the …
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed …
Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update
Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) …
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming …